Cancer marker tests are often proposed for three intended uses: screening, diagnosis, and monitoring. For each intended use, performance characteristics need to be well defined. The utility of a marker in a given setting depends heavily on two predominant performance characteristics-sensitivity and specificity. These parameters must be established with respect to the intended clinical use of the marker. The value of the marker in a particular situation also depends on the effectiveness of therapy for the malignancy. In reviewing a cancer marker test, the US Food and Drug Administration focuses on both the proposed intended use statement and the clinical utility of the marker. The sponsor is expected to provide specific claims data in support of the safety and effectiveness of the device through well-designed and -executed clinical Class III devices are associated with greater risk and are subject to premarket approval to ensure their safety and effectiveness (3). To ifiustrate the premarket review and approval process, we will use cancer markers for two reasons: these substances (analytes) and their respective technologies belong to the class Ill category, and the markers are currently the subject of much interest and concern.
Indexing Term: government regulation of medical devices
The Medical Device Amendments to the Food, Drug, and Cosmetic Act were enacted in 1976. That law directed the US Food and Drug Administration (FDA) to regulate medical devices under those control levels that are necessary to ensure safety and effectiveness.4 To achieve this goal, the law required the agency to issue regulations placing all devices on the market at that time into one of three regulatory classes (Table 1) . To initiate the classification process, the agency was directed to obtain a classification recommendation from an advisory panel.
In 1978, the Immunology Advisory Panel recommended that new cancer markers be placed in class III because these devices had certain potential risks associated with their intended medical uses.
The Safe Medical Devices Act of 1990, the first major revision of the 1976 amendments, extended the previous amendments, which had allowed the use of two major mechanisms to bring a medical device to market: pre- be classified as class I or II and can be compared to a device that is legally, commercially marketed (substantial equivalence).
Class III devices are associated with greater risk and are subject to premarket approval to ensure their safety and effectiveness (3). To ifiustrate the premarket review and approval process, we will use cancer markers for two reasons: these substances (analytes) and their respective technologies belong to the class Ill category, and the markers are currently the subject of much interest and concern.
The manufacturer of a device placed in class Ill must submit an application for premarket approval that contains safety and effectiveness data from clinical investigations ( and actual clinical specimens. Accuracy and precision must be measured over the dynamic range for which the class III device is intended to be used. Sensitivity and specificity must be considered with respect to the intended clinical use of the product.
Using widely accepted criteria reported in the scientific literature, the FDA examines each class III product and evaluates it against the manufacturer's own labeling claims as to how well it performs and compares it with other class Ill products marketed for that purpose.
Each claim (e.g., screening vs monitoring) must be supported by statistically significant scientific data. Changing the labeling of a device for a particular use can mean that the device may have to meet different sets of supporting data requirements.
For example, a cancer marker proposed for longitudinal monitoring will require clinical data accumulated over time to support that claim. A claim for screening or diagnosis would require different types of data in support of these claims. 
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Evaluation of Cancer Markers
The FDA review and evaluation of an 1VD cancer marker test focuses on the proposed intended use statement and the clinical utility of the device. The success of a premarket application depends on the sponsor to establish testing criteria, to prove all specific clinical claims, and to confirm the safety and effectiveness of the device through well-designed clinical studies. The nonclinical laboratory studies required for a premarket approval application are those generally associated with the development of an assay system. The characterization of both the antigen and antibody(ies) are very important and critically evaluated.
Testing The predictive value is calculated by the formula frequently referred to as Bayes' formula. Before a cancer marker test result is evaluated for its intended clinical use, an understanding of the epidemiological sensitivity, specificity, and prevalence as well as analytical interpretation of sensitivity and specificity are required to establish clinical utifity of cancer markers. The predictive value of a marker changes significantly when there is a change in the prevalence of the type of cancer in the population under study. For example, in a hypothetical situation, we might know from the value for sensitivity and specificity that the marker test was positive in 95% of cancer patients and negative in 95% of patients without cancer; i.e., it has a sensitivity of 95% and a specificity of 95%. The relationship between these two parameters and the prevalence of the type of cancer under In this article, we have presented the basic concepts and applications of premarket review and approval process for cancer markers. The relationship between a particular cancer-related analyte and the clinical status of the patient must be emphasized, and tests designed to measure cancer-related analyte concentrations must be accurate and precise. Continued technological advances are expected to provide not only new analyte markers but also new technologies to detect them. These technological advances may provide an opportunity to extend the use of markers to early diagnosis and detection. it is commonly accepted that early intervention offers the most promise for better prognosis in cancer patients In addition, the use of panels of two or more approved markers may contribute
